Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
B. infantis 35624 vs L. acidophilus: B. infantis 35624 has the stronger overall evidence (5 vs 5/10); they're alternatives for improve digestion — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
B. infantis 35624 wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (1)
Outcomes where both B. infantis 35624 and L. acidophilus have evidence — compare verdict strength side-by-side.
1 x 10^8 CFU (100 million) daily — the dose that won the only head-to-head dose comparison; 1 x 10^10 CFU also beat placebo in a separate trial, so higher doses are not ruled out
Any time of day
Freeze-dried capsule standardized to 35624 at 1 x 10^8 CFU
1-100 billion CFU (10^9 to 10^11) per serving — the range FDA reviewed without objection for L. acidophilus DDS-1 in foods generally (GRAS Notice GRN 871); La-14 was noticed at 1 billion CFU per 250 g serving (GRN 502) (the one cited trial that states a dose used 10 billion CFU a day)
Any time of day
A product naming its strain (e.g. NCFM, DDS-1, La-14, La-5)
4 weeks
4 weeks
n/a
n/a
Weeks
Weeks
Course of antibiotics
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
Am J Gastroenterol (2006) · Rct · n=362
1 x 10^8 CFU significantly superior to placebo AND to all other doses for the primary endpoint of abdominal pain
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.
Gastroenterology (2005) · Rct · n=77
Beat placebo on composite score and on abdominal pain, bloating/distention and bowel-movement difficulty for most treatment weeks
Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
Curr Med Res Opin (2017) · Meta analysis
Single-strain 35624 had no effect on abdominal pain, bloating/distention, or bowel-habit satisfaction
Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial.
Nutrients (2020) · Rct · n=330
Randomised, double-blind, placebo-controlled multicentre trial in 330 adults with IBS (Rome IV), allocated 1:1:1 to placebo, L. acidophilus DDS-1 alone or B. lactis UABla-12 alone, each at 1 × 10^10 CFU/day for six weeks
The effects of the DDS-1 strain of lactobacillus on symptomatic relief for lactose intolerance - a randomized, double-blind, placebo-controlled, crossover clinical trial.
Nutr J (2016) · Crossover
Randomised, double-blind, placebo-controlled crossover trial in adults with self-reported lactose intolerance confirmed by a lactose challenge: 4 weeks of DDS-1 or maltodextrin placebo once daily, with a 2-week washout
Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial.
Lancet (2013) · Rct · n=2981
Randomised, double-blind, placebo-controlled multicentre trial in 2,981 inpatients aged 65 and over taking antibiotics, given a multistrain preparation of lactobacilli and bifidobacteria (6 × 10^10 organisms per day for 21 days) or placebo
B. infantis 35624 has a higher evidence score (5/10 vs 5/10) and wins in 1 of 3 categories.
For improve digestion, B. infantis 35624 has a higher relevance score (58 vs 55).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.